Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Staphylococcal Infections | 17 | 2021 | 176 | 3.210 |
Why?
|
Cross Infection | 22 | 2023 | 304 | 2.690 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 12 | 2023 | 124 | 2.130 |
Why?
|
Bacteremia | 14 | 2017 | 117 | 2.070 |
Why?
|
Community-Acquired Infections | 13 | 2021 | 78 | 1.790 |
Why?
|
Staphylococcus aureus | 8 | 2021 | 85 | 1.620 |
Why?
|
Methicillin Resistance | 7 | 2012 | 31 | 1.610 |
Why?
|
Hospitals | 6 | 2022 | 157 | 1.580 |
Why?
|
Catheter-Related Infections | 9 | 2023 | 28 | 1.550 |
Why?
|
Anti-Bacterial Agents | 11 | 2021 | 401 | 1.320 |
Why?
|
Patient Safety | 2 | 2022 | 50 | 1.290 |
Why?
|
Infection Control | 10 | 2015 | 174 | 1.230 |
Why?
|
Intensive Care Units | 10 | 2020 | 312 | 1.160 |
Why?
|
Staphylococcal Skin Infections | 4 | 2011 | 14 | 1.060 |
Why?
|
Health Information Exchange | 2 | 2022 | 5 | 0.980 |
Why?
|
Population Surveillance | 7 | 2010 | 118 | 0.940 |
Why?
|
Quality Indicators, Health Care | 3 | 2022 | 39 | 0.880 |
Why?
|
Hospitalization | 4 | 2022 | 319 | 0.830 |
Why?
|
Catheterization, Central Venous | 7 | 2015 | 42 | 0.830 |
Why?
|
United States | 19 | 2022 | 2344 | 0.800 |
Why?
|
Pandemics | 2 | 2022 | 237 | 0.800 |
Why?
|
Humans | 67 | 2023 | 29814 | 0.790 |
Why?
|
Soft Tissue Infections | 4 | 2011 | 28 | 0.770 |
Why?
|
Medicare | 1 | 2022 | 123 | 0.770 |
Why?
|
Electronic Health Records | 4 | 2015 | 66 | 0.680 |
Why?
|
Benchmarking | 2 | 2019 | 42 | 0.680 |
Why?
|
Betacoronavirus | 1 | 2020 | 75 | 0.660 |
Why?
|
Quality of Health Care | 2 | 2019 | 138 | 0.660 |
Why?
|
Critical Illness | 1 | 2020 | 127 | 0.650 |
Why?
|
HIV Infections | 6 | 2013 | 997 | 0.650 |
Why?
|
Chicago | 15 | 2020 | 867 | 0.640 |
Why?
|
Coronavirus Infections | 1 | 2020 | 86 | 0.630 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 89 | 0.630 |
Why?
|
Risk Assessment | 2 | 2020 | 683 | 0.610 |
Why?
|
Risk Factors | 13 | 2021 | 2465 | 0.560 |
Why?
|
Sepsis | 2 | 2010 | 147 | 0.540 |
Why?
|
Fluoroquinolones | 2 | 2006 | 25 | 0.520 |
Why?
|
Disease Outbreaks | 3 | 2011 | 89 | 0.520 |
Why?
|
Male | 33 | 2023 | 15851 | 0.480 |
Why?
|
Female | 34 | 2023 | 16412 | 0.480 |
Why?
|
Adult | 27 | 2023 | 8741 | 0.470 |
Why?
|
Middle Aged | 26 | 2022 | 9960 | 0.470 |
Why?
|
Nose | 2 | 2013 | 35 | 0.420 |
Why?
|
Algorithms | 4 | 2014 | 400 | 0.410 |
Why?
|
Drug Resistance, Bacterial | 3 | 2009 | 52 | 0.400 |
Why?
|
Prisons | 2 | 2013 | 12 | 0.400 |
Why?
|
Retrospective Studies | 15 | 2020 | 3325 | 0.390 |
Why?
|
Creatine Kinase | 4 | 2015 | 33 | 0.390 |
Why?
|
HIV | 1 | 2012 | 92 | 0.390 |
Why?
|
Phenotype | 5 | 2021 | 362 | 0.380 |
Why?
|
Myositis | 4 | 2015 | 40 | 0.380 |
Why?
|
Bacteriuria | 1 | 2010 | 5 | 0.370 |
Why?
|
Knowledge Bases | 1 | 2010 | 3 | 0.350 |
Why?
|
Chlorhexidine | 4 | 2012 | 61 | 0.350 |
Why?
|
Aged | 17 | 2022 | 9620 | 0.340 |
Why?
|
Public Health | 2 | 2022 | 62 | 0.330 |
Why?
|
Neutropenia | 1 | 2008 | 21 | 0.320 |
Why?
|
Cohort Studies | 8 | 2022 | 1952 | 0.310 |
Why?
|
Incidence | 7 | 2014 | 759 | 0.300 |
Why?
|
Public Housing | 1 | 2007 | 4 | 0.290 |
Why?
|
Anti-Infective Agents, Local | 4 | 2012 | 52 | 0.290 |
Why?
|
Confidentiality | 3 | 2015 | 11 | 0.280 |
Why?
|
Databases, Factual | 4 | 2015 | 331 | 0.280 |
Why?
|
Baths | 3 | 2012 | 27 | 0.270 |
Why?
|
Case-Control Studies | 4 | 2022 | 641 | 0.270 |
Why?
|
Academic Medical Centers | 5 | 2015 | 142 | 0.270 |
Why?
|
Genomics | 3 | 2021 | 43 | 0.260 |
Why?
|
Developing Countries | 1 | 2005 | 21 | 0.260 |
Why?
|
Gram-Negative Aerobic Bacteria | 1 | 2005 | 4 | 0.260 |
Why?
|
Aspartate Aminotransferases | 2 | 2015 | 19 | 0.250 |
Why?
|
Alanine Transaminase | 2 | 2015 | 23 | 0.250 |
Why?
|
Fomites | 1 | 2004 | 4 | 0.240 |
Why?
|
Carrier State | 3 | 2013 | 52 | 0.240 |
Why?
|
Disinfection | 1 | 2004 | 11 | 0.240 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 4 | 2015 | 39 | 0.240 |
Why?
|
Adolescent | 7 | 2022 | 2332 | 0.230 |
Why?
|
Skin | 3 | 2014 | 118 | 0.230 |
Why?
|
Patient-Centered Care | 2 | 2015 | 61 | 0.230 |
Why?
|
Regression Analysis | 2 | 2015 | 298 | 0.220 |
Why?
|
Text Messaging | 1 | 2023 | 14 | 0.220 |
Why?
|
Pneumonia, Ventilator-Associated | 1 | 2023 | 17 | 0.220 |
Why?
|
Urinary Tract Infections | 1 | 2023 | 32 | 0.210 |
Why?
|
Prognosis | 4 | 2022 | 874 | 0.210 |
Why?
|
Microbial Sensitivity Tests | 4 | 2021 | 110 | 0.210 |
Why?
|
Illinois | 4 | 2021 | 241 | 0.210 |
Why?
|
Hospitals, Public | 4 | 2015 | 31 | 0.200 |
Why?
|
Skin Care | 2 | 2012 | 14 | 0.190 |
Why?
|
Clostridium Infections | 2 | 2012 | 19 | 0.190 |
Why?
|
Medical Record Linkage | 3 | 2015 | 5 | 0.190 |
Why?
|
Disease Transmission, Infectious | 1 | 2021 | 21 | 0.190 |
Why?
|
Comorbidity | 2 | 2020 | 504 | 0.190 |
Why?
|
Occupational Exposure | 1 | 2021 | 25 | 0.190 |
Why?
|
Palliative Care | 1 | 2022 | 149 | 0.180 |
Why?
|
Young Adult | 7 | 2022 | 1966 | 0.180 |
Why?
|
Enterocolitis, Pseudomembranous | 2 | 2010 | 16 | 0.180 |
Why?
|
Sexual and Gender Minorities | 1 | 2020 | 25 | 0.170 |
Why?
|
Multivariate Analysis | 3 | 2013 | 332 | 0.170 |
Why?
|
Health Personnel | 1 | 2021 | 115 | 0.170 |
Why?
|
Time Factors | 6 | 2022 | 1641 | 0.170 |
Why?
|
Aged, 80 and over | 7 | 2022 | 4930 | 0.170 |
Why?
|
Decision Support Systems, Clinical | 2 | 2010 | 10 | 0.170 |
Why?
|
Sentinel Surveillance | 2 | 2009 | 8 | 0.170 |
Why?
|
Adenosine A2 Receptor Agonists | 1 | 2018 | 11 | 0.160 |
Why?
|
Prevalence | 3 | 2020 | 494 | 0.150 |
Why?
|
Purines | 1 | 2018 | 34 | 0.150 |
Why?
|
Medical Records Systems, Computerized | 2 | 2009 | 12 | 0.150 |
Why?
|
Myocardial Ischemia | 1 | 2018 | 49 | 0.150 |
Why?
|
Pyrazoles | 1 | 2018 | 50 | 0.150 |
Why?
|
Medical Audit | 1 | 2017 | 7 | 0.150 |
Why?
|
Antimicrobial Stewardship | 1 | 2017 | 10 | 0.150 |
Why?
|
Electrocardiography | 1 | 2018 | 219 | 0.150 |
Why?
|
Inappropriate Prescribing | 1 | 2017 | 6 | 0.150 |
Why?
|
Hygiene | 2 | 2008 | 13 | 0.150 |
Why?
|
Medical Staff, Hospital | 1 | 2017 | 19 | 0.150 |
Why?
|
Internal Medicine | 1 | 2017 | 32 | 0.140 |
Why?
|
Dermatomyositis | 2 | 2014 | 16 | 0.140 |
Why?
|
Bacterial Infections | 2 | 2009 | 66 | 0.140 |
Why?
|
Prospective Studies | 3 | 2023 | 1823 | 0.140 |
Why?
|
Heart Valves | 1 | 2016 | 5 | 0.140 |
Why?
|
Endocarditis | 1 | 2016 | 9 | 0.140 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2016 | 22 | 0.130 |
Why?
|
Time-to-Treatment | 1 | 2016 | 33 | 0.130 |
Why?
|
Cardiac Surgical Procedures | 1 | 2016 | 43 | 0.130 |
Why?
|
Hospital Units | 1 | 2015 | 9 | 0.130 |
Why?
|
Bacterial Load | 2 | 2013 | 13 | 0.130 |
Why?
|
Multicenter Studies as Topic | 1 | 2015 | 77 | 0.130 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 20 | 0.130 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 532 | 0.130 |
Why?
|
Civil Defense | 1 | 2015 | 7 | 0.130 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 7 | 0.130 |
Why?
|
Gram-Positive Bacteria | 2 | 2012 | 16 | 0.130 |
Why?
|
Prednisone | 1 | 2015 | 68 | 0.130 |
Why?
|
Software | 1 | 2015 | 72 | 0.120 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2012 | 41 | 0.120 |
Why?
|
Hospital Information Systems | 1 | 2014 | 5 | 0.120 |
Why?
|
HIV-1 | 2 | 2009 | 451 | 0.120 |
Why?
|
Bacterial Proteins | 2 | 2014 | 76 | 0.120 |
Why?
|
Health Services Research | 1 | 2015 | 42 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 1 | 2015 | 102 | 0.120 |
Why?
|
Registries | 2 | 2022 | 191 | 0.120 |
Why?
|
Immunosuppressive Agents | 1 | 2015 | 135 | 0.120 |
Why?
|
Computer Communication Networks | 1 | 2014 | 4 | 0.120 |
Why?
|
Pharynx | 1 | 2014 | 14 | 0.120 |
Why?
|
Nasal Cavity | 1 | 2014 | 35 | 0.120 |
Why?
|
Information Dissemination | 1 | 2014 | 22 | 0.120 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 2014 | 4 | 0.120 |
Why?
|
Sensitivity and Specificity | 3 | 2011 | 558 | 0.120 |
Why?
|
International Classification of Diseases | 2 | 2011 | 23 | 0.110 |
Why?
|
Hospitals, Urban | 2 | 2015 | 35 | 0.110 |
Why?
|
Genotype | 2 | 2012 | 399 | 0.110 |
Why?
|
Models, Statistical | 2 | 2012 | 132 | 0.110 |
Why?
|
Molecular Epidemiology | 3 | 2021 | 26 | 0.110 |
Why?
|
Stroke | 1 | 2016 | 294 | 0.100 |
Why?
|
Reproducibility of Results | 5 | 2014 | 802 | 0.100 |
Why?
|
Colectomy | 1 | 2012 | 20 | 0.100 |
Why?
|
Gram-Negative Bacteria | 2 | 2009 | 37 | 0.100 |
Why?
|
Treatment Outcome | 5 | 2016 | 3561 | 0.100 |
Why?
|
Virulence | 1 | 2011 | 15 | 0.100 |
Why?
|
RNA, Viral | 2 | 2009 | 159 | 0.100 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2011 | 9 | 0.100 |
Why?
|
Length of Stay | 2 | 2010 | 320 | 0.100 |
Why?
|
Klebsiella Infections | 1 | 2011 | 56 | 0.100 |
Why?
|
Clinical Coding | 1 | 2011 | 6 | 0.090 |
Why?
|
Klebsiella pneumoniae | 1 | 2011 | 61 | 0.090 |
Why?
|
beta-Lactamases | 1 | 2011 | 72 | 0.090 |
Why?
|
Delivery of Health Care | 2 | 2023 | 156 | 0.090 |
Why?
|
Models, Economic | 1 | 2010 | 9 | 0.090 |
Why?
|
Computer Security | 3 | 2015 | 8 | 0.090 |
Why?
|
Pulmonary Embolism | 1 | 2011 | 59 | 0.090 |
Why?
|
Quality Assurance, Health Care | 1 | 2010 | 48 | 0.090 |
Why?
|
Geography | 1 | 2010 | 22 | 0.090 |
Why?
|
Spondylitis, Ankylosing | 1 | 2010 | 44 | 0.090 |
Why?
|
Cluster Analysis | 1 | 2010 | 53 | 0.090 |
Why?
|
Automation | 1 | 2010 | 11 | 0.090 |
Why?
|
Hospital Costs | 1 | 2010 | 68 | 0.090 |
Why?
|
Drug Utilization | 1 | 2009 | 27 | 0.090 |
Why?
|
Branched DNA Signal Amplification Assay | 1 | 2009 | 1 | 0.090 |
Why?
|
Arthritis, Infectious | 1 | 2010 | 58 | 0.080 |
Why?
|
Viremia | 1 | 2009 | 37 | 0.080 |
Why?
|
Drug Utilization Review | 1 | 2009 | 7 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 156 | 0.080 |
Why?
|
Health Care Costs | 1 | 2009 | 70 | 0.080 |
Why?
|
Disease Notification | 1 | 2008 | 4 | 0.080 |
Why?
|
Pattern Recognition, Automated | 1 | 2008 | 9 | 0.080 |
Why?
|
Data Collection | 1 | 2009 | 108 | 0.080 |
Why?
|
Feces | 2 | 2008 | 97 | 0.080 |
Why?
|
Viral Load | 1 | 2009 | 208 | 0.080 |
Why?
|
Phylogeny | 2 | 2021 | 63 | 0.080 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2008 | 20 | 0.080 |
Why?
|
Gram-Positive Cocci | 1 | 2008 | 5 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2008 | 22 | 0.080 |
Why?
|
Foodborne Diseases | 1 | 2008 | 3 | 0.080 |
Why?
|
Drug Administration Routes | 1 | 2008 | 12 | 0.080 |
Why?
|
Program Evaluation | 1 | 2009 | 135 | 0.080 |
Why?
|
Models, Theoretical | 1 | 2008 | 94 | 0.080 |
Why?
|
Drainage | 1 | 2008 | 50 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2008 | 232 | 0.080 |
Why?
|
Survival Analysis | 1 | 2008 | 310 | 0.080 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2007 | 25 | 0.070 |
Why?
|
Drug Resistance, Viral | 1 | 2007 | 40 | 0.070 |
Why?
|
Critical Care | 1 | 2010 | 242 | 0.070 |
Why?
|
Genome, Bacterial | 2 | 2017 | 14 | 0.070 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 73 | 0.070 |
Why?
|
Anti-HIV Agents | 1 | 2007 | 173 | 0.070 |
Why?
|
DNA, Bacterial | 2 | 2017 | 49 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 194 | 0.070 |
Why?
|
Hip Joint | 1 | 2010 | 357 | 0.070 |
Why?
|
Heart-Assist Devices | 1 | 2005 | 22 | 0.060 |
Why?
|
Virus Diseases | 1 | 2004 | 16 | 0.060 |
Why?
|
Mycoses | 1 | 2004 | 22 | 0.060 |
Why?
|
Polymyositis | 2 | 2014 | 10 | 0.060 |
Why?
|
Mass Screening | 1 | 2005 | 180 | 0.060 |
Why?
|
Severity of Illness Index | 1 | 2008 | 1126 | 0.060 |
Why?
|
Poisson Distribution | 2 | 2015 | 25 | 0.050 |
Why?
|
Therapies, Investigational | 1 | 2022 | 7 | 0.050 |
Why?
|
Prosthesis-Related Infections | 1 | 2005 | 215 | 0.050 |
Why?
|
Social Determinants of Health | 1 | 2022 | 28 | 0.050 |
Why?
|
Methicillin | 1 | 2021 | 6 | 0.050 |
Why?
|
Molecular Typing | 1 | 2021 | 7 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 245 | 0.050 |
Why?
|
Maryland | 1 | 2021 | 8 | 0.050 |
Why?
|
Georgia | 1 | 2021 | 12 | 0.050 |
Why?
|
Seroepidemiologic Studies | 1 | 2021 | 20 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2017 | 334 | 0.050 |
Why?
|
Biomarkers | 2 | 2014 | 704 | 0.050 |
Why?
|
Homosexuality, Male | 1 | 2020 | 24 | 0.050 |
Why?
|
Disease Progression | 1 | 2022 | 812 | 0.040 |
Why?
|
Linear Models | 2 | 2010 | 258 | 0.040 |
Why?
|
Hospitals, Teaching | 2 | 2009 | 33 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2021 | 216 | 0.040 |
Why?
|
Patient Discharge | 2 | 2010 | 151 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2022 | 384 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 970 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2022 | 1462 | 0.040 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 75 | 0.040 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2017 | 6 | 0.040 |
Why?
|
Exercise Test | 1 | 2018 | 124 | 0.040 |
Why?
|
Feedback | 1 | 2017 | 32 | 0.040 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2018 | 57 | 0.040 |
Why?
|
Glasgow Outcome Scale | 1 | 2016 | 2 | 0.030 |
Why?
|
Computed Tomography Angiography | 1 | 2016 | 24 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2016 | 30 | 0.030 |
Why?
|
Cerebral Angiography | 1 | 2016 | 30 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2016 | 154 | 0.030 |
Why?
|
Urban Health Services | 1 | 2015 | 13 | 0.030 |
Why?
|
Safety-net Providers | 1 | 2015 | 8 | 0.030 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2015 | 2 | 0.030 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 5 | 0.030 |
Why?
|
Management Audit | 1 | 2014 | 2 | 0.030 |
Why?
|
Interinstitutional Relations | 1 | 2015 | 10 | 0.030 |
Why?
|
Epidemiological Monitoring | 1 | 2014 | 7 | 0.030 |
Why?
|
Patient Selection | 1 | 2016 | 234 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2015 | 110 | 0.030 |
Why?
|
Muscle Strength | 1 | 2015 | 129 | 0.030 |
Why?
|
Genetic Markers | 1 | 2014 | 45 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 456 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2015 | 104 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2015 | 329 | 0.030 |
Why?
|
Information Systems | 1 | 2014 | 21 | 0.030 |
Why?
|
Membrane Transport Proteins | 1 | 2014 | 51 | 0.030 |
Why?
|
Liver Diseases | 1 | 2014 | 40 | 0.030 |
Why?
|
Quality Improvement | 1 | 2014 | 158 | 0.030 |
Why?
|
Contact Tracing | 1 | 2011 | 6 | 0.020 |
Why?
|
Multilocus Sequence Typing | 1 | 2011 | 10 | 0.020 |
Why?
|
Indiana | 1 | 2011 | 17 | 0.020 |
Why?
|
Bacterial Typing Techniques | 1 | 2011 | 12 | 0.020 |
Why?
|
Utah | 1 | 2011 | 2 | 0.020 |
Why?
|
Baltimore | 1 | 2011 | 14 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2011 | 44 | 0.020 |
Why?
|
Drug Costs | 1 | 2010 | 17 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 36 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2010 | 48 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 120 | 0.020 |
Why?
|
Soaps | 1 | 2010 | 9 | 0.020 |
Why?
|
Biological Assay | 1 | 2010 | 9 | 0.020 |
Why?
|
Hospitals, Special | 1 | 2009 | 6 | 0.020 |
Why?
|
APACHE | 1 | 2009 | 28 | 0.020 |
Why?
|
Organizational Policy | 1 | 2009 | 15 | 0.020 |
Why?
|
Culture Media | 1 | 2009 | 36 | 0.020 |
Why?
|
Blood | 1 | 2009 | 25 | 0.020 |
Why?
|
Long-Term Care | 1 | 2009 | 56 | 0.020 |
Why?
|
Acute Disease | 1 | 2010 | 225 | 0.020 |
Why?
|
CD4 Antigens | 1 | 2009 | 37 | 0.020 |
Why?
|
Hospitals, University | 1 | 2009 | 40 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 398 | 0.020 |
Why?
|
Chronic Disease | 1 | 2011 | 508 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2009 | 67 | 0.020 |
Why?
|
Escherichia coli O157 | 1 | 2008 | 2 | 0.020 |
Why?
|
Salmonella | 1 | 2008 | 5 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2008 | 67 | 0.020 |
Why?
|
Diarrhea | 1 | 2008 | 47 | 0.020 |
Why?
|
HIV Reverse Transcriptase | 1 | 2007 | 9 | 0.020 |
Why?
|
HIV Protease | 1 | 2007 | 9 | 0.020 |
Why?
|
Computer Simulation | 1 | 2008 | 218 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2007 | 157 | 0.020 |
Why?
|
Inpatients | 1 | 2009 | 141 | 0.020 |
Why?
|
Treatment Failure | 1 | 2007 | 161 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2008 | 129 | 0.020 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2005 | 4 | 0.020 |
Why?
|
Mutation | 1 | 2007 | 396 | 0.020 |
Why?
|
Heart Transplantation | 1 | 2005 | 37 | 0.020 |
Why?
|